

In Vitro Effect of Peruvian Antimicrobial Agents on *Borrelia burgdorferi*

by

Priyanka A.S. Theophilus M.S.

Postgraduate Research Fellow

Advisor

Eva Sapi Ph.D.

Lyme Disease Research Group, Department of Biology and Environmental Sciences, University of New Haven, West Haven, CT 06516

Lyme Disease – The fastest growing epidemic




Lyme Disease – The most common vector-borne infectious disease in the Northern United States

Number of people diagnosed with Lyme Disease each year in the US $\approx 300,000$

*Rapidly spreading throughout Europe and northeast Asia
(The Centers for Disease Control and Prevention)*

Reported Cases of Lyme Disease -- United States, 2013



1 dot placed randomly within county of residence for each confirmed case

How long did we know about Lyme disease?



The autopsy of Ötzi the Iceman (5,300-year-old mummy) revealed the presence of DNA sequences of *Borrelia*



New discoveries of ticks fossilized in amber show that the bacteria which cause it may have been lurking around for 15 million years



Borrelia burgdorferi




Exists in different morphological forms

Round body and biofilm form under stressful conditions


(Sapi E *et al*; 2011)

In favorable conditions, round body form revert back to spirochetes

Round body and biofilm forms show higher resistance to antimicrobials (Sapi E *et al*; 2012)



Spirochetes and Round body forms



Biofilm

Conventional Antibiotics – Advantage/Disadvantage



Doxycycline - Choice of Lyme disease treatment

Doxycycline failed to cure infected mice (Moody K. D *et al*; 1994)

Spirochetes are capable of persisting in doxycycline treated mice and nonhuman primate hosts (Hodzic E *et al*; 2014) (Embers M. E *et al*; 2012)

Our research group has proven that all forms have different sensitivities to antimicrobial agents (Sapi E *et al*; 2011)

Borrelia frequently becomes resistant to antibiotic treatment

Known to have unfavorable side effects (Chang E.T *et al*; 2005)



Alternative therapies for Lyme disease



Enzyme therapy

Homeopathics

Herbal antimicrobial agents

Bee venom therapy

Chi machine/light beam generator

Hyperbaric oxygen therapy

Detox therapy

Photon therapy

Ozone therapy



Clinical study on Peruvian Herbal extracts



Utilizes several herbal extracts from the Cowden support program designed to eliminate microbes in advanced Lyme disease patients

(Dr. Richard Horowitz, ILADS, 2010)

Study conducted on **over 100 Lyme disease patients who did not respond to standard antibiotic treatment**

Samento and Banderol plus 8 other natural products used for the first 78 days

Later, 4 other antimicrobial agents (Enula, Mora, Cumanda, Houttuynia) are used in rotation along with Samento and Banderol

Effective for **more than 80%** of the patients

Another independent European clinical study

Dr. Armin Schwarzbach – Study conducted on 20 advanced Lyme disease patients
(1st Ireland Lyme Disease conference, 2012)


The herbal extracts from the Cowden support program markedly improved symptoms
in **80% of the patients**

Improved laboratory test results in **90% of the patients**


The doses were equivalent to thousands of times the recommended doses for
humans

Caused no acute or chronic organ damage or any adverse effects

Samento and Banderol (Datar A *et al*; 2010)




Samento




Banderol


Control




Doxycycline




Samento



Banderol



Samento + Banderol



Research question



Can we find additional effective antimicrobial agents from the list of Peruvian herbs for *Borrelia burgdorferi* ?

Peruvian Medicinal Antimicrobial Agents - Benefits



Have significant antimicrobial, antiprotozoal and antiviral properties

Safer to use

Cost effective

Might provide effective therapeutic options



Name	Species	Activity of the agent	Reported effectiveness against the following pathogens
Mora	Premix of 3 plant extract: <i>Rubus fruticosus</i> , <i>Achillea millefolium</i> and <i>Calycophyllum spruceanum</i>	Antibacterial	<i>Staphylococcus aureus</i> ²⁴ , <i>Streptococcus pneumoniae</i> and <i>Clostridium perfringens</i> ²⁵
Enula	<i>Inula helenium</i> , <i>Mirabilis jalapa</i> and <i>Vitis tiliifolia</i>	Antibacterial and antifungal	<i>Bacillus cereus</i> , <i>Pseudomonas aeruginosa</i> , <i>Staphylococcus aureus</i> ^{26,27} , <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> ^{20,27} and <i>Aspergillus parasiticus</i> ²⁸
Stevia	<i>Stevia rebaudiana</i>	Antimicrobial	<i>Staphylococcus aureus</i> , <i>Bacillus subtilis</i> , <i>Vibrio cholera</i> ²⁹ , <i>Bacillus subtilis</i> , <i>Micrococcus luteus</i> , <i>Serratia marcescens</i> , <i>Pseudomonas aeruginosa</i> , <i>Bacillus megaterium</i> , <i>Escherichia coli</i> and <i>Proteus vulgaris</i> ³⁰
Cumanda	<i>Campsiandra angustifolia</i>	Anti-parasitic, anti-fungal, anti-viral	<i>Plasmodium falciparum</i> ³¹
Houttuynia	<i>Houttuynia cordata</i>	Antibacterial	<i>Salmonella typhimurium</i> ³²
Samento	<i>Uncaria tomentosa</i>	Antibacterial	<i>Borrelia burgdorferi</i> ⁹ and <i>Pseudomonas aeruginosa</i> ³³
Banderol	<i>Otoba species</i>	Antibacterial	<i>Borrelia burgdorferi</i> ⁹
Takuna	<i>Cecropia strigosa</i>	Antibacterial	<i>Escherichia coli</i> and <i>Bacillus subtilis</i> ³⁴
Barberry	<i>Mahonia aquifolium</i>	Antimicrobial, antifungal	<i>Staphylococcus aureus</i> and <i>Candida sp</i> ³⁵
Lakato	<i>Echinacea angustifolia</i>	Antibacterial	<i>Escherichia coli</i> , <i>Proteus mirabilis</i> , <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> ³⁶
Quina	<i>Cinchona calisaya</i>	Antimalarial	<i>Plasmodium falciparum</i> ³⁷

Experimental conditions



Borrelia burgdorferi B31 laboratory strain

The herbal extracts were prepared in alcohol and formulated by Nutramedix Inc®

Positive control - Doxycycline (10 µg/ml)

Direct counting method– Seeded a concentration of 1×10^5 cells for 5 days

Crystal violet assay- Seeded a concentration of 5×10^6 cells for 7 days

Treatment regime – Antimicrobial agents treated for every 24 hrs for subsequent 3 days


In vitro evaluation of antimicrobial agents against *Borrelia burgdorferi*



Direct counting method – Counting live spirochetes and round body forms stained with special dyes

Live cells – Green color

Dead cells – Red color



Spirochetes and Round body forms

Qualitative and quantitative analysis of the attached biofilm form after treatment with antimicrobial agents




Crystal violet staining assay


Live dead assay

Live cells – Green color

Dead cells – Red color




Crystal violet staining



Live dead

RESULTS


Direct counting method – Live spirochetes and round body forms




Antimicrobial agents	% reduction – Spirochetes	% reduction – Round body forms
Doxycycline (25 µg/ml)	85%	Increase
Mora	55%	50%
Cumanda	23%	20%
Houttuynia	11%	4%
Enula	44%	32%
Takuna	12%	27%
Samento	63%	Increase
Banderol	29%	20%
Houttuynia + Enula	22%	61%
Cumanda + Mora	14%	60%
Samento + Banderol	68%	45%

Effectiveness of antimicrobial agents on the spirochete and round body forms evaluated using direct counting method. (A) Counting live *Borrelia* spirochetes after treatment with antimicrobial agents (B) Counting live round body forms of *Borrelia* after treatment with antimicrobial agents (n=3 ± SD, *p≤ 0.05, **p≤ 0.01)

Do the antimicrobial agents also work on biofilms?



Quantitating attached biofilms by standard crystal violet staining method




Antimicrobial agents	% reduction in biomass after 72 hr treatment
Doxycycline (25 µg/ml)	Increase
Mora	30%
Cumanda	18%
Houttuynia	15%
Enula	50%
Takuna	40%
Samento	30%
Banderol	43%
Hottuynia + Enula	55%
Cumanda + Mora	45%
Samento + Banderol	75%

Quantitative analysis measuring the total biomass after 72 h treatment measured by crystal violet staining technique. 25% grain alcohol (1:50 dilution) was used as a negative control. (n=3 ± SD, *p≤ 0.05, **p≤ 0.01)


Antimicrobial treated *Borrelia* biofilms stained using BacLight viability kit



Doxycycline




Houttuynia + Enula




The micrographs represent the biofilm form of *Borrelia burgdorferi* to the antimicrobial agents after 72 h treatment measured by fluorescent microscopy using BacLight viability kit

Live cells – Green color
Dead cells – Red color


Cumanda + Mora



Samento + Banderol



Control (B31)



Conclusion



Agents effective against spirochetes
Mora
Enula
Samento + Banderol

Agents effective against round bodies
Mora
Houttuynia + Enula
Cumanda + Mora
Samento + Banderol

Agents effective against biofilms
Mora
Enula
Takuna
Banderol
Houttuynia + Enula
Cumanda + Mora
Samento + Banderol

- Clinical studies + *in vitro* studies show the effectiveness of the antimicrobial agents against *Borrelia burgdorferi*
- However the efficacy of these antimicrobial agents must be further reinforced by *in vivo* studies
- These antimicrobial agents could provide an effective therapeutic approach for Lyme disease patients

References



- Brisson, D., Vandermause, M. F., Meece, J. K., Reed, K. D., & Dykhuizen, D. E. (2010). Evolution of northeastern and midwestern *Borrelia burgdorferi*, United States. *Emerging Infectious Diseases*, 16, 911–917. doi:10.3201/eid1606.090329
- Sal, M. S., Li, C., Motalab, M. A., Shibata, S., Aizawa, S., & Charon, N. W. (2008). *Borrelia burgdorferi* uniquely regulates its motility genes and has an intricate flagellar hook-basal body structure. *Journal of Bacteriology*, 190, 1912–1921. doi:10.1128/JB.01421-07
- Charon, N. W., Goldstein, S. F., Marko, M., Hsieh, C., Gebhardt, L. L., Motaleb, M. A., Wolgemuth, C. W., Limberger, R. J., & Rowe, N. (2009). The flat-ribbon configuration of the periplasmic flagella of *Borrelia burgdorferi* and its relationship to motility and morphology. *Journal of Bacteriology*, 191, 600–607. doi:10.1128/JB.01288-08
- Sapi, E., Kaur, N., Anyanwu, S., Luecke, D. F., Datar, A., Patel, S., Rossi, M., & Stricker, R. B. (2011). Evaluation of in-vitro antibiotic susceptibility of different morphological forms of *Borrelia burgdorferi*. *Infection and Drug Resistance*, 4, 97–113. doi:10.2147/IDR.S19201
- Wormser, G. P., Nadelman, R. B., Dattwyler, R. J., Dennis, D. T., Shapiro, E. D., Steere, A. C., Rush, T. J., Rahn, D. W., Coyle, P. K., Persing, D. H., Fish, D., & Luft, B. J. (2000). Practice guidelines for the treatment of Lyme disease. *Clinical Infectious Diseases*, 31, S1–S14. doi:10.1086/314053
- Dattwyler, R. J., Wormser, G. P., Rush, T. J., Finkel, M. F., Schoen, R. T., Grunwaldt, E., Franklin, M., Hilton, E., Bryant, G. L., Agger, W. A., & Maladorno, D. (2005). A comparison of two treatment regimens of ceftriaxone in late Lyme disease. *Wiener Klinische Wochenschrift*, 117, 393–397. doi:10.1007/s00508-005-0361-8
- Datar, A., Kaur, N., Patel, S., Luecke, D. F., & Sapi, E. (2010). *In vitro* effectiveness of samento and banderol herbal extracts on the different morphological forms of *Borrelia burgdorferi*. *Townsend Letter*.
- Krause, P. J., Foley, D. T., Burke, G. S., Christianson, D., Closter, L., & Spielman, A. (2006). Reinfection and relapse in early Lyme disease. *The American Journal of Tropical Medicine and Hygiene*, 75, 1090–1094.
- Hodzic, E., Imai, D., Feng, S., & Barthold, S. W. (2014). Resurgence of persisting non-cultivable *Borrelia burgdorferi* following antibiotic treatment in mice. *Plos One*, 9 (1), 1-11.

References



- Eskow, E., Rao, R. V, & Mordechai, E. (2001). Concurrent infection of the central nervous system by *Borrelia burgdorferi* and *Bartonella henselae*: evidence for a novel tick-borne disease complex. *Archives of neurology*, 1357–1363. doi:10.1001/archneur.58.9.1357
- Chang, E. T., Smedby, K. E., Hjalgrim, H., Schollkopf, C., Porwit-MacDonald, A., Sundstrom, C., Tani, E., d'Amore, F., Melbye, M., Adami, H., & Glimelius, B. (2005). Medication use and risk of non-Hodgkin's lymphoma. *American Journal of Epidemiology*, 162, 965–974. doi:10.1093/aje/kwi311
- Elkayam, O., Yaron, M., & Caspi, D. (1999). Minocycline-induced autoimmune syndromes: An overview. *Seminars in Arthritis and Rheumatism*. doi:10.1016/S0049-0172(99)80004-3
- Goldstein, N. S., Bayati, N., Silverman, A. L., & Gordon, S. C. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. *American journal of clinical pathology*, 591–598 (2000). doi:10.1309/KV2J-VX6Q-L95V-VDE4
- Klempner, M. S., Hu, L. T., Evans, J., Schmid, C. H., Johnson, G. M., Trevino, R. P., Norton, D., Levy, L., Wall, D., McCall, J., Kosinski, M., & Weinstein, A. (2001). *Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease*. *The New England journal of medicine*, 345, 85–92. doi:10.1056/NEJM200107123450202
- Alban, P. S., Johnson, P. W., & Nelson, D. R. (2000). Serum-starvation-induced changes in protein synthesis and morphology of *Borrelia burgdorferi*. *Microbiology*, 146, 119–127.
- Sapi, E., Bastian, S. L., Mpoy, C. M., Scott, S., Rattelle, A., Pabbati, N., Poruri, A., Burugu, D., Theophilus, P. A. S., Pham, T. V., Datar, A., Dhaliwal, N. K., MacDonald, A., Rossi, M. J., Sinha, S. K & Luecke, D. F. (2012). Characterization of biofilm formation by *Borrelia burgdorferi* *in vitro*. *PLoS ONE*, 7, 1-11. doi:10.1371/journal.pone.0048277
- Miklossy, J., Kasas, S., Zurn, A. D., McCall, S., Yu, S., & McGeer, P. L. (2008). Persisting atypical and cystic forms of *Borrelia burgdorferi* and local inflammation in Lyme neuroborreliosis. *Journal of Neuroinflammation*, 5, 40. doi:10.1186/1742-2094-5-40
- Valerio, L. G., & Gonzales, G. F. (2005). Toxicological aspects of the South American herbs cat's claw (*Uncaria tomentosa*) and maca (*Lepidium meyenii*): A critical synopsis. *Toxicological Reviews*. doi:10.2165/00139709-200524010-00002
- Jayaraman, S., Manoharan, M. S., & Illanchezian, S. (2008). In-vitro antimicrobial and antitumor activities of *Stevia rebaudiana* (Asteraceae) leaf extracts. *Tropical Journal of Pharmaceutical Research*, 7(4), 1143-1149.

References



- Tadhani, M. B., & Subhash, R. (2007). *In Vitro* Antimicrobial Activity of *Stevia rebaudiana* bertonii Leaves. *Tropical Journal of Pharmaceutical Research*. doi:10.4314/tjpr.v5i1.14633
- Horowitz, R.I. (2010). Plenary presentation at the ILADS (International Lyme and Associated Diseases Society) conference held at New Jersey, USA.
- Schwarzbach, A. (2012). Plenary presentation at the Ireland's first Lyme disease conference held at Dublin, Ireland.
- Steere, A. C., Grodzicki, R. L., Kornblatt, A. N., Craft, J. E., Barbour, A. G., Burgdorfer, W., Schmid, G. P., Johnson, E., & Malawista, S. E. (1983). The spirochetal etiology of Lyme disease. *New England Journal of Medicine*, 308(13), 733-740.
- Burgdorfer, W., Barbour, A. G., Hayes, S. F., Benach, J. L., Grunwaldt, E., & Davis, J. P. (1982). Lyme disease-a tick-borne spirochetosis?. *Science*, 216(4552), 1317-1319.
- Moody, K. D., Adams, R. L., & Barthold, S. W. (1994). Effectiveness of antimicrobial treatment against *Borrelia burgdorferi* infection in mice. *Antimicrobial agents and chemotherapy*, 38(7), 1567-1572.
- Embers, M. E., Barthold, S. W., Borda, J. T., Bowers, L., Doyle, L., Hodzic, E., ... & Philipp, M. T. (2012). Persistence of *Borrelia burgdorferi* in rhesus macaques following antibiotic treatment of disseminated infection. *PLoS One*, 7(1), e29914.
- Adsul, V.B., Khatiwora, E., Torane, R., & Deshpande, N.R. (2012). Antimicrobial activities of *Ipomoea carnea* leaves. *J. Nat. Plant Resour*, 2 (5), 597-600.
- Bautista, E., Serrano, M. F., & Miranda, R. P. (2015). Jalapinoside, a macrocyclic bisdesmoside from the resin glycosides of *Ipomea purga*, as a modulator of multidrug resistance in human cancer cells. *J. Nat. Prod*, 78 (1), 168-172.
- Meira, M., Silva, E. P., David, J. M., & David, J. P. (2012). Review of the genus *Ipomoea*: traditional uses, chemistry and biological activities. *Revista Brasileira de Farmacognosia Brazilian Journal of Pharmacognosy*, 22(3), 682-713.
- Feng, J., Auwaerter, P. G., & Zhang, Y. (2015). Drug combinations against *Borrelia burgdorferi* persists in vitro: Eradication achieved by using Daptomycin, Cefoperazone and Doxycycline. *Plos One*, 10 (3), 1-15.
- Feng, J., Wang, T., Shi, W., Zhang, S., Sullivan, D., Auwaerter, P. G., & Zhang, Y. (2014). Identification of novel activity against *Borrelia burgdorferi* persists using an FDA approved drug library. *Emerging microbes and infections*. 3. 1- 8.

Acknowledgements



We are grateful to The Joshua foundation and The University of New Haven for all their support

Thank
You